Department of Gynaecology and obstetrics, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou, China.
J Matern Fetal Neonatal Med. 2024 Dec;37(1):2395490. doi: 10.1080/14767058.2024.2395490. Epub 2024 Aug 29.
To compare the efficacy of simultaneous and sequential administration of oxytocin and intrauterine balloons in labor induction.
The databases of Cochrane Library, Web of Science, PubMed, ClinicalTrials.gov, and Embase were thoroughly searched from their inception to November 2023. Randomized controlled trials (RCTs) investigating the simultaneous and sequential use of oxytocin and intrauterine balloons for labor induction in pregnancy were included. The meta-analysis was performed using RevMan 5.3 statistical software. Heterogeneity among the selected studies was evaluated using the statistic. Dichotomous outcomes were estimated using relative risk (RR) with corresponding 95% confidence intervals (CI), while continuous outcomes were measured as the mean difference (MD).
A total of eight studies, involving a total of 1,315 nulliparous and multiparous women with an unfavorable cervix, were included in the systematic review. Moreover, a subgroup analysis was conducted, separately evaluating nulliparous and multiparous women. Compared with the sequential groups, simultaneous use of oxytocin and intrauterine balloons resulted in a significantly higher rate of delivery within 24h in nulliparas (RR = 1.30, 95%CI:1.04, 1.63, = 0.02), a higher rate of vaginal delivery within 24h in multiparas (RR = 1.32, 95%CI:1.15,1.51, < 0.00001), a superior rate of delivery within 12h and a shorter time to delivery in both nulliparas and multiparas. No statistically significant differences were observed in cesarean delivery and maternal and neonatal adverse outcomes between the sequential and simultaneous groups.
These findings provide support for the simultaneous use of intrauterine balloons and oxytocin during labor induction in nulliparous women. Additionally, this approach may also prove beneficial for multiparas.
比较缩宫素与宫腔内水囊序贯和同时给药在引产中的疗效。
系统检索 Cochrane 图书馆、Web of Science、PubMed、ClinicalTrials.gov 和 Embase 数据库,检索时间从建库至 2023 年 11 月。纳入比较缩宫素与宫腔内水囊序贯和同时给药用于妊娠引产的随机对照试验(RCT)。采用 RevMan 5.3 统计软件进行 meta 分析。采用 Q 检验评估所选研究的异质性。二分类结局采用相对危险度(RR)及其 95%置信区间(CI)表示,连续性结局采用均数差(MD)表示。
系统评价共纳入 8 项 RCT,共计 1315 例初产妇和经产妇宫颈条件不佳的孕妇。此外,还进行了亚组分析,分别评估初产妇和经产妇。与序贯组相比,同时使用缩宫素和宫腔内水囊可显著提高初产妇 24 小时内分娩率(RR=1.30,95%CI:1.04,1.63, = 0.02)、24 小时内阴道分娩率(RR=1.32,95%CI:1.15,1.51, < 0.00001)、12 小时内分娩率,缩短产程时间。序贯组与同时组剖宫产率、母婴不良结局发生率差异无统计学意义。
这些结果支持在初产妇引产中同时使用宫腔内水囊和缩宫素,也可能对经产妇有益。